<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256148</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1830-WAI-201</org_study_id>
    <nct_id>NCT04256148</nct_id>
  </id_info>
  <brief_title>ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared
      to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a 4-week Screening period, 13-week Primary Treatment period, and
      optional Extended Treatment period (up to 2 years).
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study is withdrawn due to the global impact of the COVID-19 pandemic.
  </why_stopped>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants randomized in 1:1:1:1 ratio to 1 of 4 study arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Of Participants With ≥ 2 Grams (g)/Deciliter (dL) Increase In Hemoglobin (Hgb) From Baseline</measure>
    <time_frame>Baseline (Day 1) through Day 92</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number Of Units Of Packed Red Blood Cells (pRBCs) Transfused</measure>
    <time_frame>Day 15 through Day 92</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline To Day 92 In Quality Of Life, Assessed Via EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Questionnaire</measure>
    <time_frame>Baseline, Day 92</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline To Day 92 In Quality Of Life, Assessed Via Functional Assessment Of Cancer Therapy Anemia (FACT-AN) Questionnaire</measure>
    <time_frame>Baseline, Day 92</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Weekly Hgb Measurements With Change From Baseline ≥ 2 g/dL</measure>
    <time_frame>Day 1 through Day 92</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Needing New WAIHA Rescue Medication Or Increase In Dose Of WAIHA Medication</measure>
    <time_frame>Day 15 through Day 92</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Warm Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1830</intervention_name>
    <description>Administered via intravenous (IV) infusion</description>
    <arm_group_label>ALXN1830 Dosing Regimen 1</arm_group_label>
    <arm_group_label>ALXN1830 Dosing Regimen 2</arm_group_label>
    <arm_group_label>ALXN1830 Dosing Regimen 3</arm_group_label>
    <other_name>SYNT001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (sterile liquid diluent) administered via IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Primary or secondary WAIHA, diagnosed at least 6 weeks prior to Screening

          -  Failed or not tolerated at least 1 prior WAIHA treatment regimen, for example,
             corticosteroids, rituximab, azathioprine, cyclophosphamide, cyclosporine,
             mycophenolate mofetil, danazol, or vincristine

          -  Hemoglobin &lt; 10 g/dL and ≥ 6 g/dL

          -  Positive direct antiglobulin test (Coombs) (IgG positive, complement C3 [C3] positive
             or negative)

          -  Evidence of active hemolysis including any of the following: a) Lactate dehydrogenase
             (LDH) &gt; upper limit of normal (ULN), b) Haptoglobin &lt; lower limit of normal (LLN), c)
             Indirect bilirubin &gt; ULN

          -  Total IgG &gt; 500 mg/dL

        Key Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) infection (positive HIV-1 or HIV-2 antibody test)

          -  Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexion Study Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Warm autoimmune hemolytic anemia</keyword>
  <keyword>WAIHA</keyword>
  <keyword>Immunoglobulin G (IgG)-mediated autoimmune disorder</keyword>
  <keyword>Pathogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

